A Review of Pfizer’s STING-ADC Technology: FcγR-Mediated Myeloid Cell Uptake and Intracellular Payload Retention

Introduction

Gruber et al. (2026) in their study “Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models” provide a critical advancement in cancer immunotherapy. The study introduces the development of non-cleavable STING agonist antibody-drug conjugates (ncSTING-ADCs), which utilize Fcγ receptor (FcγR) interactions to direct the STING agonist payload to myeloid cells in the tumor microenvironment (TME).

This approach overcomes key limitations faced by STING agonists, such as systemic toxicity, poor retention within the TME, and limited antitumor efficacy.

Figure 1. Structure of ncSTING-ADC

This article aims to critically review the findings of Gruber et al.’s research, interpreting their significance, and evaluating the potential impact on the future development of immunostimulatory antibody-drug conjugates (ISACs), particularly those based on STING agonists.

We will explore the study's novel use of FcγR-mediated targeting and the implications of these findings for improving cancer immunotherapy.

FcγR Binding: A Paradigm Shift in ADC Design

One of the key innovations in this study is the use of FcγR binding in the design of ncSTING-ADCs, which contrasts with traditional ADC strategies. In conventional ADCs, the Fc region is often engineered to avoid FcγR binding to prevent off-target immune activation. However, Gruber et al. demonstrate that FcγR binding can enhance the antitumor activity of STING agonists.

Their study shows that FcγR binding directs the STING agonist payload to myeloid cells in the TME, enhancing the immune response.

Figure 2. FcγR-dependent immune-mediated tumor cell killing induced by tumor-targeted STING ADCs.

The authors point out that while FcγR binding is not essential for the efficacy of the ncSTING-ADCs in all tumor models, it plays a crucial role in certain cases. In models like the CD228-LL2 lung cancer model, FcγR binding was necessary for effective antitumor responses. However, in other models, the FcγR binding enhanced activity but was not a requirement.

This finding suggests that the therapeutic value of FcγR binding in ADCs may vary depending on the tumor type and immune cell composition within the TME.

Figure 3. FcγR-dependent antitumor activity of tumor-targeted ncSTING-ADCs in multiple tumor models.

FcγR-Mediated Uptake and Intracellular Payload Retention: A Synergistic Mechanism

Another significant aspect of the study is the use of non-cleavable linkers in ncSTING-ADCs. This design ensures that the STING agonist payload remains within the immune cell after FcγR-mediated internalization, enabling sustained activation of the STING pathway.

Unlike cleavable linkers, which result in rapid payload release and clearance from the cells, non-cleavable linkers help maintain the payload inside the immune cells, providing continuous immune stimulation.

Gruber et al. highlight that the metabolite Compound 2, released from the non-cleavable linker, exhibits slower efflux rates, resulting in prolonged retention within the cells. This prolonged retention is crucial for maintaining persistent STING pathway activation, which is essential for generating long-lasting immune responses.

In comparison with cleavable linker–based ADCs, the study emphasizes the advantages of non-cleavable linkers in sustaining immune activation within the TME, ultimately improving the therapeutic efficacy of STING-based therapies.

The Safety Profile of FcγR-Mediated Activation: Targeting the Tumor Microenvironment

A significant concern with many immune-based therapies is the risk of systemic immune activation and associated side effects. Gruber et al. address this concern by showing that FcγR-mediated immune activation in ncSTING-ADCs is largely confined to the TME.

This localized activation occurs because the Fab region of the ADC binds to tumor-specific antigens, ensuring that immune responses are directed specifically at the tumor, rather than being broadly activated throughout the body.

This “spatial isolation” of immune activation represents a key design advantage of the ncSTING-ADC strategy. While free Compound 2, the STING agonist, caused widespread cytokine release and systemic immune activation, ncSTING-ADCs led to only modest increases in IL-6 and other inflammatory cytokines, without significant adverse effects.

This demonstrates that targeted delivery of immune-activating payloads can minimize systemic toxicity while still providing effective immune responses within the TME.

Key Insights and Implications for ISAC Design

Gruber et al.’s findings offer valuable insights for the design of next-generation immunostimulatory antibody-drug conjugates (ISACs), particularly those utilizing STING agonists. The following key points emerge from the study:

1. FcγR Binding for Targeted Immune Activation: FcγR binding is shown to enhance the delivery of STING agonists to myeloid cells within the TME. This finding suggests that FcγR targeting could be a promising strategy for improving the effectiveness of immune-modulatory therapies, particularly in the context of STING-based ADCs.

2. Non-Cleavable Linkers for Sustained Payload Retention: Non-cleavable linkers are advantageous for maintaining prolonged intracellular retention of the payload, ensuring continuous activation of the STING pathway. This design could be applied not only to STING agonists but also to other immune agonists requiring sustained activation.

3. Localized Immune Activation to Minimize Systemic Toxicity: By restricting immune activation to the TME, ncSTING-ADCs minimize the risk of systemic inflammation. This localized approach enhances the safety profile of ADCs, making them more suitable for clinical use.

These insights underscore the potential of FcγR-mediated targeting and non-cleavable linkers in improving the efficacy and safety of ADCs, offering new strategies for the development of ISACs and other immune therapies.

Conclusion

Gruber et al.’s study provides an important advancement in the design of ADCs, particularly ADCs carrying immunostimulatory payloads such as STING agonists. By incorporating FcγR-mediated targeting and non-cleavable linkers, ncSTING-ADCs enhance the delivery of the STING agonist to immune cells in the TME and ensure sustained activation of the STING pathway.

These innovations address key challenges in cancer immunotherapy, including systemic toxicity, poor TME retention, and limited therapeutic efficacy.

The findings from this study have significant implications for the future development of immunostimulatory antibody-drug conjugates (ISACs) and other immune-based therapies. By improving the safety and efficacy of STING-based treatments, ncSTING-ADCs represent a promising new direction in cancer immunotherapy, with the potential to offer more effective and targeted treatment options for patients.

Experimental Tools for FcγR Interaction Studies

As Fcγ receptor engagement increasingly emerges as an important factor in antibody therapeutics and immunostimulatory ADCs, reliable experimental systems are essential for characterizing Fc–FcγR interactions and evaluating Fc effector functions during antibody development.

To support such studies, ACROBiosystems provides a range of research tools for Fc receptor biology, including:

• Recombinant Fc receptor proteins (FcRn, FcγRI/IIa/IIb/IIIa)

• TR-FRET assay kit for Fc–FcγR binding

• Engineered cell lines for ADCC and ADCP functional evaluation

In addition, a pre-configured Fc receptor protein panel integrating multiple Fc receptors is available to facilitate parallel interaction studies. All proteins are produced through standardized workflows and validated by SDS-PAGE, SEC-MALS, and binding-based assays such as SPR, BLI, or ELISA.

>>> Click to Learn More Fc Receptor Products

References

Gruber DR, Cummins EJ, Zeng W, Ulrich M, Smith K, Long M, Spahr K, Higgins S, Hinricher K, Langalia A, Krumm K, Olson DJ, Grogan B, Mazahreh R, Gupta P, Burke PJ, Smith A, Senter PD, Gardai SJ, Hill AG, Gray EE. Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2026 Mar 2;25(3):457-468. doi: 10.1158/1535-7163.MCT-25-0108. PMID: 41159384.